Talal Khader, MD
Internal Medicine · Southfield, MINPI 1033314513
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.8% of the total across 181 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 29 manufacturers reported payments, led by AstraZeneca at 25.6% of the total. 2025 is the largest year on record at $1,418, 9.6 times the $147 reported in 2019. Among internal medicine clinicians in MI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 181 payments — averaging $25.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- GSK$1K
- Aimmune Therapeutics, Inc.$263
- Lilly USA, LLC$237
- AbbVie$229
- AMAG Pharmaceuticals, Inc.$216
- plus $1K from 23 others
Across 106 payments — averaging $2975.87 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Romark Laboratories, LC$132K
- AbbVie$120K
- GSK$25K
- Boehringer Ingelheim$21K
- Indivior Inc.$17K
What the payments were for
- Food & beverage$4,56599%
- Education$571%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 39 | $1,185 |
| GSK | 50 | $1,163 |
| Aimmune Therapeutics, Inc. | 3 | $263 |
| Lilly USA, LLC | 8 | $237 |
| AbbVie(2 entities) | 13 | $229 |
| AMAG Pharmaceuticals, Inc. | 2 | $216 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 19 | $193 |
| Orexo US, Inc. | 4 | $147 |
| Ironwood Pharmaceuticals, Inc | 7 | $135 |
| Daiichi Sankyo Inc. | 1 | $123 |
| Astellas Pharma US Inc | 1 | $115 |
| Otsuka America Pharmaceutical, Inc. | 4 | $68 |
| Novo Nordisk | 3 | $62 |
| Verona Pharma, Inc. | 3 | $61 |
| Dexcom, Inc. | 3 | $58 |
| Pfizer | 3 | $55 |
| Braeburn Inc. | 3 | $46 |
| Indivior Inc. | 2 | $39 |
| Lundbeck LLC | 2 | $34 |
| Amgen | 2 | $30 |
| Mylan Specialty L.p. | 1 | $25 |
| Endo Pharmaceuticals Inc. | 1 | $21 |
| Viatris Specialty LLC | 1 | $20 |
| Boehringer Ingelheim | 1 | $20 |
| Medtronic | 1 | $18 |
| Exact Sciences | 1 | $17 |
| Supernus Pharmaceuticals, Inc. | 1 | $15 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $15 |
| Nestle Healthcare Nutrition Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AIRSUPRA$250
- ZENPEP$249
- FERAHEME$216
- TRELEGY ELLIPTA$125
- INJECTAFER$123
- MOUNJARO$116
- XTANDI$115
How this compares
$4,622 in reported general payments places this provider in the 90th percentile of 4,567 internal medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 166 | $105,563 |
| JardianceEmpagliflozin | 138 | $97,420 |
| TrulicityDulaglutide | 78 | $73,850 |
| EliquisApixaban | 81 | $66,155 |
| OzempicSemaglutide | 58 | $61,044 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 201 | $37,451 |
| MounjaroTirzepatide | 32 | $34,557 |
| JanuviaSitagliptin Phosphate | 41 | $30,959 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 48 | $30,126 |
| XareltoRivaroxaban | 35 | $29,693 |
| EntrestoSacubitril/Valsartan | 40 | $26,455 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 46 | $25,757 |
| LinzessLinaclotide | 35 | $21,108 |
| FarxigaDapagliflozin Propanediol | 30 | $20,537 |
| BrixadiBuprenorphine | 11 | $10,921 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $1,163 | $118,278196 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $237 | $108,407110 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $20 | $106,043155 claims |
| PfizerEliquis | $55 | $66,15581 claims |
| Novo NordiskOzempic | $62 | $61,04458 claims |
| AstraZenecaBreztri Aerosphere, Farxiga, Brilinta | $1,185 | $57,56492 claims |
| AbbVieLinzess, Namzaric | $229 | $28,32048 claims |
| Indivior Inc.Suboxone | $39 | $25,75746 claims |
| Braeburn Inc.Brixadi | $46 | $10,92111 claims |
| Orexo US, Inc.Zubsolv | $147 | $8,35814 claims |
| Astellas Pharma US IncMyrbetriq | $115 | $5,16812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,567 internal medicine providers in Michigan.
Other internal medicine in Southfield
- Adam FormanSouthfield$453K
- Terry SmithAnn Arbor$2.3M
- Michael ValituttoKalamazoo$1.8M
- Ulka VaishampayanAnn Arbor$996K
- Tina AbrahamPontiac$834K
- Steven KatzmanLivonia$715K
- Saroj NeupaneDetroit$373K
- James BazziDearborn Heights$368K
- Mohamad HatahetWaterford$352K
- A FendrickAnn Arbor$347K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.